AbbVie Pays $10.9B for Apogee and Its Inflammation Pipeline
What AbbVie is buying is a pipeline, not a product line. Apogee Therapeutics, a clinical-stage biotechnology company, has agreed to be acquired by AbbVie in an all-cash transaction valued at $10.9 billion, or $135.11 per share. Joele Frank, Wilkinson Brimmer Katcher advised Apogee.
Apogee’s candidates target inflammatory and immunological diseases, among them atopic dermatitis, the most common form of eczema, and asthma. Its lead program, zumilokibart, is an antibody aimed at IL-13, a protein that helps drive both conditions. None of it is on the market yet. The price is a wager on data still to come. Atopic dermatitis affects tens of millions of people, and the market for advanced treatments has drawn nearly every large drugmaker, which makes a differentiated antibody a contested prize.
Robert Michael, AbbVie’s CEO, framed the purchase around the company’s existing immunology franchise. “The acquisition of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need better options while also creating significant long-term value for shareholders,” he said.
He added that AbbVie is “uniquely positioned to rapidly advance these programs and continue to transform the standard of care in inflammatory diseases.”
That positioning carries weight for a company whose immunology business has long leaned on Humira and its successors Skyrizi and Rinvoq. A next-generation IL-13 antibody, dosed less often than current options if trials hold up, would extend that franchise into the back half of the decade.
The terms are straightforward. Boards at both companies unanimously approved the all-cash deal. Closing is expected in the third quarter, subject to Apogee shareholder approval and customary regulatory clearances. AbbVie has said it expects the acquisition to become accretive to adjusted diluted earnings per share beginning in 2032. That timeline shows how much of the value still sits in candidates working through the clinic. Paying entirely in cash, rather than stock, signals confidence in the pipeline and avoids diluting AbbVie shareholders.
Joele Frank, Wilkinson Brimmer Katcher partners Andrea Rose and Aura Reinhard, along with managing director Greg Klassen and director Carly King, represented Apogee.
Deals for clinical-stage biotechs turn on conviction about molecules that have not yet reached patients. AbbVie is paying nearly $11 billion for a company defined by what its lead antibody might do for eczema and asthma sufferers, and for the room that molecule could create as older immunology products age. The clinic will settle whether the number was right. For now, it marks one of the larger bets on inflammation this year.
